These follow-on drugs are on a path to upend the current standards of care.
News & Analysis: Novartis
Novartis' new gene therapy, Zolgensma, may be the most expensive drug ever, but there's much more to the story.
Getting end payers on board with a seven-figure price for Zolgensma won't be easy.
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Drugmakers battle for patients.
Sometimes you have to act while the iron's hot, and that's the case with these three big-name dividend payers right now.
Novartis completed its spin-off of eye care specialist Alcon and Zogenix had a drug application rejected.
Spinning off a less-than-thrilling eye care business isn't the only reason.
A thousand gene therapies in development could get a lot more attention if these two live up to expectations this year.
Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?